Funding will support development of next generation orthopedic products that provide accelerated healing through single treatment cures Equity Funding led by CR-CP Life Science Fund, New Science Ventures, Fund+ and SRIW MONT SAINT-GUIBERT, Belgium–(BUSINESS WIRE)–November 3, 2022– Novadip Biosciences (“Novadip” or “the Company”), a clinical-stage biopharmaceutical company developing a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single treatment, today announced that it has raised an additional EUR 40 million in a Series B equity round and non-dilutive funding. The funding will accelerate the clinical development of two of Novadip’s investigational…